论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Baldo P, Cecco S
Received 29 June 2017
Accepted for publication 29 August 2017
Published 8 November 2017 Volume 2017:10 Pages 5337—5353
DOI https://doi.org/10.2147/OTT.S145105
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Amy Norman
Peer reviewer comments 2
Editor who approved publication: Dr William Cho
Abstract: Mesothelin (MSLN) is considered a promising target for cancer therapy.
Originally extracted in 1992 after the immunization of mice with a human
ovarian cancer (OC) cell line and cloned in 1996, MSLN seems to be involved in
cell adhesion and metastasis. MSLN is prevalent in mesothelia tissues but is
expressed in several human cancers, such as OC, pancreatic cancer,
mesothelioma, and lung cancer. Amatuximab (MORAb-009) is a mouse-human chimeric
monoclonal antibody with a selective affinity for MSLN. The principal mechanism
of action comprises inhibition of binding of MSLN with the antigen CA125/MUC16.
The highest phase of development is actually a Phase II trial (MORAb-009-201,
Europe). In this review, we describe the mechanism of action of amatuximab and
other MSLN-targeting novel drugs, along with a discussion about the expected
efficacy, safety, and toxicity of this promising group of agents and
implications for future research and clinical practice.
Keywords: amatuximab,
monoclonal antibody, mesothelin, antigen, mesothelioma, target therapy